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Summary
We have investigated the mechanisms whereby adoptively transferred murine CD8+ lymphocytes
mediate tumor regressions. Noncytolytic, CD8+ tumor-infiltrating lymphocytes (TIL) eradicated
established lung tumors in irradiated mice. Many cytolytic and noncytolytic CD8+ TIL cultures
specifically secreted interferon y (IFN-y) and tumor necrosis factor when stimulated with tumor
cells in vitro. The effectiveness ofTIL when adoptively transferred to micebearing micrometastases
correlated better with their ability to specifically secrete lymphokines than with theircytotoxicity
in vitro. In 14 of 15 tests, therapeutically effective TIL specifically secreted IFN-y in vitro, whereas
only 1 of 11 ineffective TIL specifically secreted IFN-y. In contrast, only 8 of 15 therapeutically
effective TIL were cytolytic. Antibodies to TNF inhibited the effectiveness of two adoptively
transferred TIL cultures. In five experiments, antibodies to IFN-y abrogated the ability of four
different CD8+ TIL cultures to mediate tumor regressions, indicating that secretion of IFN-y
is an essential part of the mechanism of action of TIL.
arly studies in mice investigating the mechanisms in-
volved in syngeneic tumor regressions mediated by the
transfer of T lymphocytes found a strong correlation between
testsofin vitro cytotoxicity and in vivo antitumor effect (1-6).
This correlation suggested that T cellswith in vitro cytotox-
icity were involved in tumor rejection in vivo and that the
mechanism of rejection was direct cytolysis. However, the
availability of mAbs to distinguish murine helper CD4+ and
cytolytic CD8+ lymphocytes enabled investigators to deplete
one or the other T cell subset and test each for their ability
to cause tumor regressions in vivo. When cytolytic CD8+
lymphocytes were depleted, the resultant noncytolytic
CD4+ lymphocytes were as capable as the nondepleted cul-
ture in eliciting rejection or preventing the outgrowth of
leukemias (7), virally induced sarcomas (8), chemically in-
duced sarcomas (9), and plasmacytomas (10) in murine models.
The possibility that these helper CD4+ cells were ac-
tivating host cytolytic CD8+ lymphocytes to mediate tumor
regression was investigated by using mice that were thymec-
tomized, lethally irradiated, and then reconstituted with T
cell-depleted, syngeneic bone marrow (B mice). The adop-
tive transfer of C138-depleted splenocytes from tumor-immune
mice to such B mice still eradicated the established tumor
(11) and prevented the outgrowth ofa subsequent tumor chal-
lenge (10). Although no cells that were cytotoxic to tumor
could be cultured from the splenocytes of these cured mice,
they were able to mediate a tumor-specific, delayed-type hyper-
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sensitivity (DTH)t reaction when re-challenged with a tumor.
These observations led investigators to propose that CD4+
lymphocytes may convey tumor resistanceby initiatinga DTH
reaction at the tumor site, thus implicating macrophages, the
cytotoxic cells in DTH reactions, as the final effectors oftumor
killing. Further support for this hypothesis came from the
observation that macrophage-activating factor (IFN-y) was
secreted in vitro in response to tumor stimulation by a
CD4+ lymphocyte line that demonstrated antitumor efficacy
in vivo (8). The secretion of IFN-y by these CD4+ lym-
phocytes was implicated in the mechanism of tumor regres-
sion when it was found that concurrent treatment with a
mAb against IFN-y blocked the effectiveness of these cells
in vivo (12).
Other investigators showed that cytolytic CD8+ clones
(13-15) and CD8+ lymphocyte cultures (16-18), when ad-
ministered with the T cell growth factor 11,2, also very effec-
tively caused the regression of established tumors. However,
there has been very little investigation on the mechanism by
which CD8+ lymphocytes eradicate tumors. In this report,
we demonstrate that the adoptive transfer of noncytolytic
CD8+ lymphocytes can mediate the regression of established
tumors in mice that were pre-irradiated to abolish host CTL
'Abbreviations used in thispaper: CM, complete media; DTH, delayed-type
hypersensitivity; GM, granulocyte/maaophage; LAK, lymphokine activated
killer; MCA, 3-methylcholanthrene; TIL, tumor-infiltrating lymphocytes.
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crete IFN-y andTNF when stimulated with a tumor; the
therapeutic effectiveness ofa largenumber oftumor-infiltrating
lymphocyte (TIL)cultures correlates better with their ability
to specifically secretelymphokinesthan with their cytotoxic
capacity in vitro. Finally, antibodies to IFN-y and TNF-C1
inhibit the in vivo antitumor effectiveness of both cytolytic
and noncytolytic CD8+ lymphocytes, thereby suggesting
that a DTH reaction may be an important mechanism by
which CD8+ lymphocytes mediate tumor regressions .
Materials and Methods
Mice.
￿
Female C57BL/6 mice (denoted B6)were obtained from
the Animal Production Colonies of the National Cancer Institute,
NIH (Frederick Facility), Frederick, MD, and from the Charles
River Breeding Laboratories, Wilmington,MA. All mice were used
at age 10 wk or older.
Tumors.
￿
TheMCA 105, 203, 205, 207, and 233 tumors are
weakly immunogenic, 3-methylcholanthrene(MCA)-induced fibro-
sarcomas of B6 origin (19) . MCA 102 is a nonimmunogenic sar-
coma . These tumors were generated in our laboratory and were
passaged subcutaneously for 10 generations, at which time a
cryopreserved vial from the first generation wasthawed and trans-
planted . MC 38 is an immunogenic colon adenocarcinoma of B6
origin (17) .
TIL Culture Conditions.
￿
TIL were cultured by immunoselec-
tion from freshly digested tumors using antiThy-1.2 mAb-coated
magnetic beads as previously described (18, 20) . TIL were then
stimulated with irradiated tumor cells and B6 splenocytes on day
1 of culture and maintained in complete medium (CM) sup-
plemented with 10-20 U/ml of rIL2 (Cetus Corp., Emeryville,
CA). FreshCM containing rIL2 was added to the culture every
3d . Every 10 d, the cultures were stimulated with irradiated (3,000
rad) tumor cells at 5 x 106 tumor cells/plate (Costar, Cambridge,
MA) . TIL clone 205-87 was generated as follows. TIL generated
from a clone ofMCA 205 were placed in 96-well, flat-bottomed
microtiter plates (Costar) inCM + 20 U/ml rIL2 at 0.3 cells/well.
Irradiated (3,000 rad) tumor and TIL were added to each well at
2 x 104 cells/well and 105 cells/well, respectively. In multiple ex-
periments, we have not observed proliferation of TIL after 3,000-
rad irradiation. The media was changed every 4 d; at day 10, the
culture was restimulated with irradiated tumor and TIL. On day
16, 3 of 192 wells were observed to have TIL colonies and these
were expanded in CM + 20U rIL2/ml with restimulation with
irradiated tumor every 10 d . MC 38 TIL "cloids" were generated
as follows . After immunobeading, TIL were plated at 100, 300,
and 1,000 cells per well in 96-well, flat-bottomed microtiter plates
in CM with 10-20 U/ml rIL2 and were stimulated with 2 x 104
irradiated (3,000 iad) tumor cells/well and 105 irradiated (3,000
rad) B6 splenocytes/well . 1wk later, cells were aspiratedfrom plates
in which half or less of the 96 wells contained proliferating cells
and were expanded for in vivo use. Lymphokine-activated killer
(LAK) cells were generatedby incubating freshB6 splenocytes in
CM + 1,000 U/ml rIL2 for 3-5 d, as previously described (18) .
In Vitro Cytotoxicity Assays.
￿
4-h "Cr release assays were per-
formed as previously described (18) . Briefly, fresh tumor targets
were labeled with "Cr and incubated with TEL effectors at varying
ratios for 4 h at 37°C . Supernatants were harvested and counted
in agammacounter. Percent lysis was calculated as follows : 100x
(experimental cpm - spontaneous cpm)/(maximalcpm - spon-
taneous cpm) . One lyric unit is defined as the number of effector
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cells needed to cause 20% lysis of 10" fresh tumor target cells and
is determined from the dose-response curves .
Fluorescence-activated Cell Sorting (FACS®)Analysis.
￿
Flow cytom-
etry analysis oflymphocyte surface phenotypes was carried outby
direct immunofluorescence using a FACS®440 flow microfluorom-
eter (BectonDickinson&Co., Mountain View, CA) . Pelleted single
cell suspensions of 106 cells were incubated for 20 min at 4°C with
20,ul of appropriately titered, FITC-conjugated, anti-Lyt-2 (mAb
2.43 ; American Type Culture Collection [ATCC], Rockville, MD)
or anti-L3T4 (mAb GK-1.5 ATCC) mAbs (Becton Dickinson&
Co.) diluted in PBS containing 1% FCS and 0.1% sodium azide,
washed, and analyzed .
Lymphokine Secretion and Detection .
￿
TIL were harvested and
plated in 2 ml of CM plus 20 U/ml rIL2 at 5 x 105 cells/well
in a 24-well plate (Costar) . 106 freshly digested andwashed tumor
cells were added in 100pl ofCM to each well.TheTIL plus tumor
mixture wasincubated at 37°C for 18 h, andthen the supernatant
was aspirated, centrifuged at 1,500 rpm to remove any cells,
decanted, and frozen at -70°C . Aliquots were then thawed and
tested in duplicate in an IFN-.y ELISA(Amgen, Thousand Oaks,
CA)andaTNFELISA(Genzyme, Boston,MA) . TheIFN-yELISA
used a solid phase, specific anti-murine IFN-'y mAb, and then a
biotinylated second, anti-murine IFN--ymAbwasadded.TheTNF
ELISAused a solid phase hamster mAb specific for murine TNF .
Agoat polyclonal anti-murineTNF second antibody wasthen used,
followed by a horseradish peroxidase--conjugated donkey anti-goat
Ig. The antibodies detect both mouseTNF-a and TNF-(3, but the
assay is specifically calibrated for TNF-cx . This ELISAhasbeen de-
termined not to detect rIW, rIL2, rIL3, recombinant granulo-
cyte/macrophage (rGM)-CSF, and rIFN--y .
Adoptive Immunotherapy Models.
￿
Forthe experiments described
in Fig. 1 and Tables 1, 3, 5, and 6, there were six mice in each
therapy group. Some mice, where indicated, received 500-rad total
body irradiation and then were injected intravenously with 5 x
105 tumor cells in 1 ml of HBSS (Biofluids, Rockville, MD) to
induce pulmonary metastases. On day 3, 5 x 106 TIL were in-
jected intravenously. Some mice were treated with 10,000U rIL2
in 0.5 ml ofHBSS intraperitoneally twice a dayon days 3-7 . On
day 15, all mice were ear tagged, randomized, killed, and pulmo-
nary metastases were enumerated in ablinded fashion as previously
described (21) .Acorrelation exists betweenpulmonary metastasis
reductionby TIL and prolongation ofmouse survival (our unpub-
lished results) .
For the TIL "cloid" experiments described in Tables 8 and 9,
three mice in each group received 500-rad total body irradiation,
and5 x 105 fresh tumor cells were injected to induce pulmonary
metastases. On day 3, 106 TIL were injected and mice were treated
with 10,000U rIL2 twice aday on days 3-7 . On day 15, all mice
were ear tagged, randomized, and pulmonary metastases were
enumerated.
Antibody Blocking Experiments.
￿
For the anti-IFN-,y antibody
blocking experiments described in Fig. 2, sixmice in each therapy
group were injected with 5 x 10 5 tumor cells on day zero to in-
duce pulmonary metastases . On day 2, 200 /Ag ofhamster anti-mu-
rine IFN-.ymAb (Genzyme) or 200 1&g ofhamster IgG(Organon
Teknika, West Chester, PA) in 0.5 ml of PBS with 0.5% human
serum albuminwas injected intraperitoneally. This anti-IFN-ymAb
was shown to inhibit macrophage activation in mice infected with
Toxoplasma gondii (22) and Listeria monocytogenes (23) . 24 h later,
various doses of TIL were injected and 10,000U rIL2 was given
intraperitoneally twice adayon days 3-7 . Mice were randomized
and pulmonary metastases were counted on day 15 .
For the antiTNF antibody blocking experiments described in
Interferon 7 and Tumor Necrosis Factor Roles in Tumor RegressionsFig . 3, pulmonary metastases were induced and TIL plus rIL2
therapywas identical to that in the anti-IFN--y mAb blocking ex-
periments. On day 2, 1 mg of rabbit anti-murine TNF antibody
(raised in New Zealandwhite rabbits immunized to recombinant
murine TNF-a [Genentech, South San Francisco, CA] as previ-
ously described [24]) or rabbit IgG(ICN Immunobiologicals, Costa
Mesa, CA) in 0.5 ml of PBS with 0.5% human serum albumin
was injected intraperitoneally . This antiTNF antibody had been
previously shown to be specific for TNF and to protect mice from
a lethal challenge with endotoxin (24) . We repeated this endotoxin
protection experiment: 1 mg of antiTNF antibody injected in-
traperitoneally 6 hbefore intraperitoneal endotoxin challenge (40
mg/kg) protected nine of nine mice, whereas two of nine mice
treated with control rabbit IgG survived for 48 h. 1 mg of anti-
TNF antisera or control rabbit IgGwas injected intraperitoneally
every morning on days 4-7 . Mice were randomized and pulmo-
nary metastases were counted on day 15 .
Statistics.
￿
Statistical analyses of in vivo experiments were per-
formed by the Wilcoxon rank sum test . The student's t test was
used for groupcomparisons in Tables 7 and 9 . Two-sidedp values
are presented in all experiments.
Results
Specifically Cytolytic TIL Are Specifically Effective In Viva
Wehadpreviouslyshownthat cultureofTIL from antigeni-
cally distinct MCAinduced sarcomas in low-dose (10-20
U/ml) rIIr2 with tumorstimulation reproducibly led to TIL
with cytolytic specificity in 4-h S1Cr release assays (18) . Our
current studies beganby investigating whethersuch cytolyt-
ically specificTIL were also specifically effective in the treat-
ment ofpulmonary micrometastases. Five TILcultures were
derived from four different MCAinduced sarcomas in low-
dose rIL2with tumorrestimulation every 10 d. AllTILwere
CD8+,CD4- by FRCS® analysis. As shown in Fig . 1, two
TIL cultures, grown fromMCA 203 and 205, were simul-
taneously tested in a 4-h 51Cr release assay and specifically
lysed their tumor of origin . Concurrently, 5 x 106 of each
of these TIL were adoptively transferred to groups of mice
that had been intravenously injected with one of the two
tumors 3 dearlier to induce pulmonary micrometastases. On
days 3-7, 10,000U rIL2 wasinjected intraperitoneally twice
a day and metastases were counted on day 15 . As shown in
IN VITRO
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Fig. 1, each TIL significantly reduced thenumber ofpulmo-
nary metastases in mice bearing the relevant tumor, but had
no effect on the number of pulmonary metastases in mice
bearing the other tumor. This experiment was repeated with
three different TIL cultures, from MCA 105, 203, and 205
(Table 1) . Again, each TIL was significantly effective against
only that tumor that it specifically lysed in vitro. These studies
IN VIVO
` As determined in a 4-h 51Cr release assay .
t 5 x 106 TIL were adoptively transferred to 500-rad pre-irradiated mice
bearing 3-d pulmonary micrometastases . On days 3-7, 10,000 U HL-2
was given intraperitoneally twice a day, and metastases were enumerted
on day 15 .
5 Significantly different than rIL-2 alone group (p < 0.002) .
Figure 1.
￿
Specifically cytolytic TIL
are specifically effective in vivo. TIL
lysed autologous tumor but not another
syngeneic sarcoma in a 4-h 51Cr release
assay . Concurrently, 5 x 106TIL were
adoptively transferred to mice bearing
3-d pulmonary metastases. 10,000 U
rIIr2 was given to all groups twice a
day on days 3-7, and metastases were
countedon day 15 . Treatmentwith each
TM IL2
￿
203L significantly reduced the number 205
TIL
￿
TIL
￿
of metastases in mice bearing autolo
Treatment
￿
gous tumor (p 4 0.004), but had no
effect on the irrelevant tumor.
Effector cells IL-2
In vivo
MCA tumor metastases
105 205 207
mean no. of metastases (SEAS#
105 TIL + 1 (1)' >250 227 (22)
205 TIL + 215 (35) 62 (9)S >250
207 TIL + 245 (5) >250 32 (5)5
None + >250 >250 >250
Table 1 . Specifically
In Vivo
Cytolytic TIL Are Specifically
In vitro
MCA tumor target
Effective
Effector cells 105 205 207
LU201106 cells"
105 TIL 100 <0.1 <0.1
205 TIL <0.1 10 <0.1
207 TIL <1 <1 >250
LAK 105 125 100Three different TIL cultures were used as positive controls; their ages
at the time of the assay were 60, 62, 65, and 120 d.
t Percent cytolysis of MCA 205 target in 4-h 51Cr release assays at an
E/T ratio of 50:1.
suggested that there was a correlation between in vitro cy-
tolysis and in vivo efficacy of cytolytic CD8+ TIL.
Nonlytic, CD8+, CD4- TIL Effectively Mediate TumorRe-
gressions in Pre-irradiated Mice.
￿
To test whether the in vitro
property of cytolysis was a necessary characteristic of ther-
apeutically effective TIL, we examined TIL that did not dem-
onstrate significant tumor lysis in 4-h "Cr release assays.
When murine TIL are grown in low-dose (10 U/ml) rIL2
with repeated tumor stimulation, approximately one third
of the resultant, rapidly proliferative, CD8+, CD4 - cultures
will be nonlytic (<10% lysis of relevant fresh tumor targets
at an E/T ratio of 50:1 in a 4-h "Cr release assay) (18). The
cytolytic capacity of culture 205-73, a nonlytic, CD8+,
CD4 - TIL culture from the MCA 205 tumor, is shown in
Table 2. In five separate "Cr release assays over a period of
Table 3.
￿
Treatment of 3-d Pulmonary Metastases with Nonlytic
" TIL culture 205-73 was 60 d old at the time of adoptive transfer of
5 x 106 TIL/mouse.
t TIL culture 205-73 was 90 d old at the time of adoptive transfer of
5 x 106 TIL/mouse.
5 On days 3-7 after tumor injection, 10,000 U rIL-2 was injected in-
traperitoneaily twice a day.
Significantly different from the group treated with rIL-2 alone(p < 0.002).
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3 mo, there was no significant lysis of MCA 205 tumor by
TIL culture 205-73, whereas other 205 TIL cultures or LAK
cells lysed the target cell in each assay. In long-term assays,
when 205-73 TIL were co-incubated with MCA 205 tumor
at a 2:1 TIL/tumor ratio for 5 d, tumor cells overgrew the
TIL culture, indicating that this culture had no detectable
short- or long-term lytic capability.
In two separate experiments, these nonlytic 205-73 TIL
were adoptively transferred to mice bearing 3-d pulmonary
micrometastases. On days 3-7, 10,000 U rIL2 was given in-
traperitoneally twice a day and metastases were enumerated
on day 15. As shown in Table 3, in both experiments these
nonlytic TIL significantly reduced the number ofpulmonary
micrometastases. Therefore, it is not necessary for a CD8+
lymphocyte to be lytic in order to mediate effective in vivo
regression of an established tumor. Furthermore, these non-
lytic TIL were effective even when the mice were pre-irradiated
with 500-rad total body irradiation, which abrogates host
lymphocyte responses (25). Therefore, these CD8+ nonlytic
TIL are not activating host CTL, but instead may be medi-
ating tumor regression through their effects on radiation-
resistant host effector cells.
Some CD8+ TIL Specifically Secrete IFN-y and TNF
When Stimulated with Tumor. These results led us to inves-
tigate whether TIL, when stimulated with tumor, secreted
lymphokines that might be able to modify the tumor or host
effector cells to lead to tumor regression. As shown in Table
4, three different TIL cultures were simultaneously stimu-
lated with weakly immunogenic relevant or irrelevant tumors,
and the amount of IFN-y secreted into the media was as-
sayed. The relevant tumor induced secretion of at least 10
times more IFN-y than that secreted by unstimulated cells
and at least three times more IFN-y than that secreted by
TIL stimulated with irrelevant tumors. Very little, ifany (0-2
U), IFN-y was detected in the supernatants of tumors in-
cubated without the addition of TIL. We also observed specific
secretion of TNF by some TIL in response to tumor stimu-
lation (Table 5). When freshly digested tumors were incubated
Table 4.
￿
Specific Secretion of IFN-y by TIL in Response
to Tumor Stimulation
Interferon 7 and Tumor Necrosis Factor Roles in Tumor Regressions
MCA tumor stimulator*
Tumor of
All TIL cultures at 2.5 x 105 cells/ml were stimulated simultaneously
with 5 x 105 tumor cells/ml. Supernatants were collected at 18 h and
assayed by ELISA .
TIL culture
105-53
origin of TIL
105
None
2
105 233 205
Ul2.5 x 101
TIL/ml
44 6 3
233-92B 233 0 7 50 2
233-90D 233 3 9 45 6
Table 2. Lack of
205-73 TIL
culture age TIL
Lysis of
205-73
MCA 205 by TIL Culture
Effector
Another 205 TIL Cx'
205-73
LAK
d
32 It ND 30
55 7 37 77
88 -1 34 ND
91 5 20 ND
118 - 3 30 49
TIL Culture 205-73
Treatment Pre-irradiation Exp . 1" Exp. 2t
No. of
metastases (SEM)
HBSS - >250 >250
HBSS + IL-2S - 180 (23) >250
HBSS + IL-2S + >250 >250
205-73 TIL + IL-2s _ 8 (2)II 8 (2)II
205-73 TIL + IL-2s + 12 (3)II 25 (3)IITable 5.
￿
In Vitro Lymphokine Secretion and Cytolysis by TIL that Were Effective In Vivo
TIL were transferred to mice bearing pulmonary micrometastases as described in Materials andMethods . Percent reduction of metastases was calcu-
lated by comparing the number of metastases in the group treated with TIL + HL-2 to the group treated with HL-2 alone .
t Secretion of lymphokines was measured in response to tumor stimulators as described in Materials and Methods . Specific lymphokine secretors
are boxed . The relevant (Rel .) tumor is the tumor of origin of the TIL ; irrelevant (Irr .) tumors are other syngeneic, weakly immunogenic MCA-
induced sarcomas .
s Percent lysis in a 4-h s'Cr release assay at an E/T ratio of 50 :1 . Lysis of target by LAK cells was >20% in all experiments . Specifically cytolytic
cultures are boxed.
in IFN-y-containing media, therewasno increased secretion
ofTNF, indicating that theTNF detected in these assays was
being secreted by TIL rather than by macrophages that may
have been present in the fresh tumor stimulator cells. Secre-
tion ofIFN-y andTNF by TIL is rapid (90% of maximum
levels are secreted in 8 h) and is areproducible characteristic
of the culture over time (26) . Optimization of the condi-
tions for lymphokine secretion by murine TIL is presented
elsewhere (26) .
TILLymphokine Secretion Correlates with In Vivo Efficacy .
￿
To
investigate what role, if any, lymphokine secretion by TIL
has in their in vivo efficacy, we simultaneously tested TIL
forlymphokine secretion and cytolysis in vitro and adoptively
transferred'these TIL into mice bearing pulmonary micro-
metastases . 26 paired in vitro and in vivo tests were done
on 13 different TIL cultures and one TIL clone (205-87)
from three different MCA-induced sarcomas . All TIL were
CD8+, CD4- by FACS® analysis and were proliferating
well at the time of adoptive transfer.
In 15 of these paired tests, therapy with TIL plus rIL2
significantly (p < 0.05) reduced the number of pulmonary
metastases compared with a group treated with rIL2 alone ;
the in vitro properties of these TIL are presented in Table
5 . In 11 tests, therapywithTILplus rIL2 did not significantly
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reduce the number of pulmonary metastases compared with
a group treated with rIL2 alone; the in vitro properties of
these therapeutically ineffective TIL are presented in Table
6. In each experiment where a TIL culture was found to be
ineffective, therewas anothergroup ofmice bearing metastases
from the same tumor in which the metastases were sig-
nificantly reducedby other effectiveTIL (i.e., apositive con-
trol group) .
As shown in Table 5, when effectiveTIL were not stimu-
lated with atumor, they constitutively released littleIFN-y.
Stimulation with a relevant tumor induced secretion of 10-50-
fold more IFN-y than that secreted by unstimulated cells,
and two- to ninefold more IFN-y than that secreted in re-
sponse to stimulationby irrelevant tumor. Secretion of IFN-y
was considered specific if the amount secreted in response
to relevant tumor stimulation was greater or equal to three
times the amount secreted by two irrelevant tumors and >15
U/2.5 x 105 cells/ml ; such values are highlighted by en-
closure in boxes in Tables 5 and 6 . Secretion of TNF was
considered specific if the amount secreted in response to rele-
vant tumor stimulation was greater or equal to three times
the amount secreted by two irrelevant tumors and >100
pg/2.5 x 105 cells/ml; these values are highlightedby boxes
in Tables 5 and 6. TIL were considered specifically cytolysic
TIL
Tumor
of
origin
Percent reduction
of pulmonary
metastases' None
IFN-.y
Rel .
secretion#
Irr . Irr. None
TNF secretion#
Rel . Irr . Irr . Rel .
Cytolysiss
Irr. Irr .
Ul2.5 x 10s cells/ml pg/2.5 x 105 cells/ml
90A 233 79 0 48 16 15 130 205 140 195 4 13 8
90B 233 99 1 55- 9 9 150 205 155 180 21 10 1
90D 233 77 1 25 8 4 55 190 290 165 6 0 -4
90D 233 99 3 45 9 6 180 250 235 195 6 2 -2
91D 233 50 1 15 5 5 70 50 70 100 8 11 3
92B 233 99 0 18 2 1 150 155 85 35 12 4 1
92B 233 99 0 50 7 2 195 195 170 130 20 10 3
92B 233 75 0 41 9 2 25 75 75 10 16 -5 -1
53 105 75 2 70 19 8 10 480 0 0 52 9 2
53 105 99 1 42 20 5 5 350 110 65 33 -2 10
53 105 74 1 53 6 17 20 905 140 200 45 0 4
87 205 99 4 65 21 ND 200 1,330 300 ND 83 1 ND
87 205 96 4 80 17 11 50 1,020 45 40 24 -6 ND
87 205 94 6 53 12 7 25 825 185 50 42 8 3
93B 205 82 1 21 3 2 150 0 0 0 12 8 NDTable 6 .
￿
In Vitro Lymphokine Secretion and Cytolysis by TIL that Were Injfective In Vivo
TIL were transferred to mice bearing pulmonary micrometastases as described in Materials and Methods . Percent reduction of metastases was calcu-
lated by comparing the number of metastases in the group treated with TIL + rIL-2 to the group treated with AL-2 alone . In each experiment,
a positive control TIL culture reduced the number of metastases 99% compared with rIL-2 alone .
t Secretion of lymphokines was measured in response to tumor stimulators as described in Materials and Methods . Specific lymphokine secretors
are boxed . The relevant (Rel .) tumor is the tumor of origin of the TIL; irrelevant (Irr.) tumors are other syngeneic, weakly immunogenic MCA-
induced sarcomas .
S Percent lysis in a 4-h s1Cr release assay at an E/T ratio of 50 :1 . Lysis of target byLAK cells was >20% in all experiments . Specifically cytolytic
cultures are boxed .
if the relevant tumor lysis was >20% and irrelevant tumor
lysis was <10% at an E/T ratio of 50:1 in a 4-h
51 Cr re-
lease assay ; these values are also highlightedby boxes in Tables
5 and 6.
Thedata in Tables 5 and6 are summarized in Table 7 . Effec-
tive TIL secreted significantly more IFN-y (45 ± 5 vs . 11
± 3 U/2.5 x 10 5 cells/ml, p< 0.0001) and TNF (416 ±
105 vs . 63 ± 15 pg/2.5 x 105 cells/ml, p = 0.009) and
were significantly more lytic (26 ± 6 vs . 2 ± 2% lysis at
an E/T ratio of 50:1, p = 0.002) than ineffective TIL.
Therelationship between specific lymphokine secretion and
cytolysis by TIL and in vivo effectiveness is summarized in
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Table 8. Specific secretion of IFN-y was associated with in
vivo effectiveness in 14 of 15 tests . There was only one case
of an effective TIL that did not specifically secrete IFN-y;
in this case, secretionofIFN-yin response to a relevant tumor
wastwicethat seen in response to an irrelevant tumor (Table
5) . In 10 of 11 tests on ineffective TIL, there was low or
nonspecific IFN-y secretion . Since 9 of 15 effective TIL did
not specifically secrete TNF and 7 of 15 effective TIL were
marginally lyticor nonlytic, neither specific secretion ofTNF
nor specific cytolysis appeared to be necessary for in vivo effec-
tiveness . However, if an IFN-y-secreting culture also spe-
cifically secreted TNF or was specifically cytolytic, this ap-
Interferon .y and Tumor Necrosis Factor Roles in Tumor Regressions
Secretion of lymphokines in response to stimulation by relevant tumor as described in Materials and Methods . Data are the mean (SEM) .
t Percent lysis of relevant tumor at an E/T ratio of 50 :1 in a 4-h s1Cr release assay . Data are the mean (SEM).
S Effective TIL + rIL-2 significantly (p <0.05) decreased the mean number ofpulmonary metastases compared with a group treated with rIL-2 alone .
II Student's t test for the difference between means of effective and ineffective TIL .
TIL
Tumor
of
origin
Percent reduction
of pulmonary
metastases" None
IFN- ,y
Rel .
secretion#
Irr. Irr . None
TNF secretion#
Rel . Irr. Irr. Rel.
Cytolysiss
Irr . Irr .
U/2.5 x 105 cells/ml pg/2.5 x 105 cells/ml
89 233 -25 1 6 3 2 35 20 0 45 -1 6 -1
89 233 -5 1 1 2 1 45 10 235 40 1 9 -3
90A 233 -5 6 40 13 12 65 110 285 130 -4 20 13
90B 233 -2 2 15 5 18 50 65 330 130 2 11 23
91A 233 -27 11 15 14 15 70 40 10 80 -1 -1 -3
91A 233 16 8 9 11 9 50 0 65 0 -9 5 0
91B 233 -39 2 9 9 6 40 35 0 70 7 23 18
91C 233 -39 1 3 2 1 60 65 30 80 4 1 2
91D 233 6 3 5 3 11 70 70 50 100 4 11 ND
84 205 0 2 7 4 2 180 150 180 180 14 3 ND
86B 205 5 2 12 3 ND 140 125 180 ND 3 2 1
Table 7 . Summary of In Vitro Lymphokine
No . of tests
Secretion and Cytolysis by TIL
IFN--y secretion"
U/2.5 x 105 cells/ml
Simultaneously Testedfor In Vivo Efficacy
TNF secretion'
pg/2.5 x 105 cells/ml
Cytolysis#
Effective TILE 15 45 (5) 416 (105) 26 (6)
Ineffective TIL 11 11 (3) 63 (15) 2 (2)
p valuell <0.0001 0.009 0.002Table 8.
￿
Relationship between Lymphokine Secretion and
Cytolysis in Vitro and Efficacy ofTIL In Vivo
In vivo effectiveness
The mean number of pulmonary metastases in mice treated with effec-
tive TIL + rIL-2 was significantly less than those treated with HL-2
alone by Wilcoxon rank sum test .
t Secretion of IFN-y (and TNF) was considered specific if the amount
secreted in response to relevant tumor stimulation was greater or equal
to three times the amount secreted by two irrelevant tumors and 315
U/2.5 x 10 5 cells/ml (and >100 pg/2 .5 x 105 cells/ml) .
S Cytolysis was considered specific in a 4-h 51Cr release assay if relevant
tumor lysis was 320% and irrelevant tumor lysis was<10% at an E/T
ratio of 50 :1 .
peared to be sufficient for in vivo effectiveness (in six of six
tests that showed specific TNF secretion, the TIL were effec-
tive; TIL were effective in eight of eight tests that showed
cytolysic specificity) .
To further investigate and substantiate these relationships,
TIL "cloids" were derived from theMC 38 adenocarcinoma
by plating dilute concentrations of TIL immediately afterim-
munobeading in 96-well plates as described in Materials and
Methods. In three separate experiments, a total of 33 "cloids"
were simultaneously tested againstMC 38 and irrelevant MCA
102 for in vitro lymphokine secretion and cytolysis and were
adoptively transferred to mice bearing MC 38 pulmonary
micrometastases. Stimulations for lymphokine secretion were
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Table 10.
￿
Relationship between Lymphokine Secretion and
Cytolysis in Vitro and Efficacy ofMC 38 TIL Cloids In Vivo
In vivo effectiveness
" Effective TEL cloids decreased the mean number ofpulmonary metastases
at least 25% compared with the group treated with rIL-2 alone .
t Secretion of IFN-y (and TNF) was considered specific if the amount
secreted in response to relevant tumor stimulation was greater or equal
to three times the amount secreted by two irrelevant tumors and 315
U/2.5 x 105 cells/ml (and >100 pg/2 .5 x 105 cells/ml) .
S Cytolysis was considered specific in a 4-h 51Cr release assay if relevant
tumor lysis was 320% and irrelevant tumor lysis was<10% at an E/T
ratio of 10:1 .
performed as previously described for the bulk TIL cultures
and the same criteria for specific lymphokine secretion were
used. Likewise, the same criteria for specific cytolysis were
used, although TIL "cloids" were tested at an E/T ratio of
10:1 . A TIL "cloid" was considered effective if the mean
number of pulmonary metastases in the treated group was
at least 25% less than the number in the group treated with
rIL2alone . The mean and median percent reductions in pul-
monary metastases for the 23 effective TIL "cloids" tested
were 87 and 99%, respectively.
23 TIL"cloids" were effective in reducing lung metastases
and 10 were ineffective (Table 9). EffectiveTIL"cloids" secreted
significantlymore IFN--y (60 ± 4 vs . 19 ± 5 U/2.5 x 10 5
Table 9 .
￿
Summary ofIn Vitro Lymphokine Secretion and Cytolysis by TIL Cloids from MC 38 Simultaneously Testedfor
In Vivo Efficacy
Secretion of lymphokines in response to stimulation by relevant tumor as described in Materials and Methods . Data are mean (SEM).
$ Percent lysis of relevant tumor at an E/T ratio of 10:1 in a 4-h s1Cr release assay .
S Effective TIL cloids + rIL-2 decreased the mean number of pulmonary metastases at least 25% compared with the group treated with HL-2 alone.
II Student's t test for the difference between means of effective and ineffective TIL .
In vitro parameter Effective"
No. of
Ineffective
tests
In vitro parameter Effective" Ineffective
No. of different
Specific$ 14 1 cloids tested
IFN-y secretion
Nonspecific 1 10 Specifict 23 5
IFN-y secretion
Nonspecific 0 5
Specific# 6 0
TNF secretion
Nonspecific 9 11 TNF secretion
Specifics 21 1
Nonspecific 2 9
Specifics 8 0
Cytolysis
Nonlytic 7 11 Cytolysis
Specifics 14 1
Nonlytic 9 9
Effective TIL "cloids"s
No . of cloids tested
23
IFN-y secretion"
U/2.5 x 105 cells/ml
60 (4)
TNF secretion"
pg/2.5 x 10 5 cells/ml
465 (64)
Cytolysis$
28 (2)
Ineffective TIL "cloids" 10 19 (5) 77 (51) 12 (3)
p valuell <0.0001 0.0008 0.0004IN VIVO EFFICACY
TIL ,
Anti-IFN 1
Figure 2 .
￿
Inhibition of TIL effectiveness by anti-IFN-ymAb. On day
-1, TIL were tested for lymphokine secretion and cytolysis as described
in Materials and Methods. IFN-y is expressed as units per 2.5 x 105
cells/ml; TNF is expressed as picograms per 2 .5 x 105 cells/ml; percent
lysis is measured in a 4-h 51Cr release assay at an E/T ratio of 50:1 . Pul-
monary metastases were induced by intravenous injection on day 0 . On
day 2, 200 Wg of anti-IFN-y mAb or hamster IgG control was injected
intraperitoneally. 5 x 106 TIL were adoptively transferred on day 3, and
10,000 U rIL2 was given intraperitoneally twice a day on days 3-7 . The
mean ± SEM number of metastases on day 15 is plotted. Treatment of
mice that received control hamster IgG with TIL + rIL2 in all experi-
ments significantly decreased the number of pulmonary metastases com-
pared with the group receiving rIL2 alone (Exp. 1, p = 0.002; Exp. 2,
p = 0.03 ; Exp. 3, p = 0.003;'Exp. 4, p = 0.002 ; Exp. 5, p - 0.002) .
In Exps . 2, 3, and 5, anti-IFN-y mAb completely inhibited the TIL (TIL
+ anti-IFN-y vs. IL2, p = NS) . In Exps . 1 and 4, anti-IFN-y inhibited
TIL effectiveness when compared with TIL + hamster IgG control (TIL
+ and-IFN-y vs. TIL + hamster IgG: Exp. 1, p = 0.02; Exp. 4, p = 0.025) .
cells/ml, p < 0.0001) andTNF (465 ± 64 vs . 77 ± 51 pg/2.5
x 105 cells/ml, p = 0.0008) and were significantly more
lytic (28 ± 2 vs. 12 ± 3% lysis at an E/T ratio of 10:1)
than ineffective TIL "cloids".The relationship between s
cytokine secretion or cytolysis by these TIL "cloids" and in
vivo effectiveness is summarized in Table 10 . All 23 effective
TIL "cloids" specifically secreted IFN-y . All but one of the
TIL "cloids" that specifically secreted TNF (21 of 22) were
effective. Similarly, all but one of the TIL "cloids" that were
specifically cytolytic (14 of 15) were effective.
Anti-IFN-y mAb Inhibits Effective TIL In Viva
￿
IFN-y was
specifically secreted in 14 of 15 tests on TIL cultures that
were therapeutically effective and in 23 of 23 tests on effec-
tiveTIL "cloids". To further delineate the role ofIFN-y secre-
tion in the therapeutic effectiveness ofTIL, TIL that specifically
secreted IFN-y were adoptively transferred to mice, bearing
pulmonary micrometastases, that had been treated with anti-
IFN-y mAb. In these experiments (Fig. 2, Exps . 1-5), TIL
were tested for lymphokine secretion and cytolysis on the
day before the induction of pulmonary micrometastases . 2 d
after metastasis induction, 200 Ag of hamster anti-murine
IFN-y mAb or 200 Wg of hamster IgG was injected in-
traperitoneally. 24 h later, 5 x 106 TIL were injected in-
travenously (except in Exp. 5, where 2 x 106 TIL were
injected) . On days 3-7, 10,000 U rIL2 were given intra-
peritoneally twice a day, and on day 15, the mice were ran-
domized and lung metastases were counted .
TheTIL in all five experiments specifically secreted IFN-y
(Fig. 2) . TheTIL in Exps. 1, 2, and 5 also specifically secreted
TNF and were specifically cytolytic. The TIL in Exps . 3 and
4 nonspecifically secreted low amounts ofTNF and were mar-
ginally cytolytic . Treatment of mice that received control ham-
ster IgG with TIL plus rIL2 in all experiments significantly
decreased the mean number of pulmonary metastases com-
pared with the group receiving rIL2 alone (Wilcoxon rank
sum test for TIL + Hamster IgG vs . 11,2 : Exp. 1, p = 0.002 ;
Exp. 2, p = 0.03; Exp. 3, p = 0.003 ; Exp . 4,p = 0.002 ;
Exp. 5, p = 0.002) . In Exps. 2, 3, and 5, anti-IFN-y mAb
completely inhibited the effectiveness ofthe TIL (TIL + anti-
IFN-y mAb vs . I1r2, p = NS) . In Exps. 1 and 4, TIL still
had some effect when administered with anti-IFN-y mAb,
but anti-IFN-y mAb significantly inhibited their effective-
nesswhen compared with TIL plus hamster IgG control an-
tibody (TIL + hamster IgG vs. TIL + anti-IFN-y : Exp . 1,
p = 0.02 ; Exp. 4, p = 0.025) . Therefore, in five of five ex-
periments with four different TIL cultures from three different
sarcomas, anti-IFN-y mAb significantly inhibited the effec-
tiveness ofTIL . Ofnote, in three of these experiments, highly
cytolytic TIL were inhibited by anti-IFN-y mAb . The data
from this series of experiments and the experiments summa-
rized in Tables 7 and 9 strongly suggest that secretion ofIFN-y
is a necessary part of the mechanism whereby both lytic and
nonlytic TIL eradicate tumor cells in vivo.
Anti-TNF Antibody Inhibits Some Elective TIL In Viva
Concurrently, during some of these experiments, the same
TIL were adoptively transferred to mice that had been treated
with antiTNF antibody. As shown in Fig. 3, three TIL cul-
tures, two of which specifically secreted TNF in response
to tumor stimulation and one that did not, were transferred
to mice bearing pulmonary micrometastases. AntiTNF an-
tibody or control rabbit IgG (1 mg) was given 6 h before
TIL transfer and daily on days 4-7 . On days 3-7 10,000 U
rIL2 was injected intraperitoneally twice a day. In two sepa-
rate experiments, although TIL culture 105-53 specifically
secretedTNF in vitro, antiTNF antibody had no significant
effect on the therapeutic efficacy of this TIL (Fig . 3, Exps .
1 and 2) . In contrast, in two experiments using TIL clone
205-87, which also specifically secreted TNF in vitro, anti-
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Figure 3 .
￿
Effect of antiTNF antibody on TIL effectiveness . On day
-1, TIL were tested for lymphokine secretion and cytolysis as described
in Materials and Methods. TNF is expressed as picograms per 2 .5 x 105
cells/ml ; IFN-.y is expressed as units per 2 .5 x 105 cells/ml; percent lysis
is measured in a 4-h 51Cr release assay at an E/T ratio of 50:1 . Pulmo-
nary metastases were induced by intravenous injection on day 0 . On day
3, 1 mg of antiTNF antibody or rabbit IgG control was injected in-
traperitodeally. 6 h later, 5 x 106 TIL were transferred, and 10,000 U
rII.2 was given intraperitoneally twice a day on days 3-7 . 1 mg of anti-
TNF antibody or rabbit IgG control was given intraperitoneally on days
4-7 . The mean ± SEM number of metastases on day 15 is plotted. By
Wilcoxon rank sum analysis, Exps. 1 and 2 : TIL + rabbit IgG vs. TIL
+ antiTNF, p = NS ; Exp. 3 : TIL + rabbit IgG vs. TIL + antiTNF,
p = 0.037; Exps. 4 and 5: TIL + rabbit IgG vs. IL2, p = 0.002; TIL
+ antiTNF vs. IL2, p - NS.
TNF antibody completely abrogated the effectiveness of the
TIL (Fig. 3, Exps . 4 and 5 : TIL + rabbit IgG vs . IIr2, p =
0.002; TIL + antiTNF vs. IL2, p = NS) . When a third
TIL culture, 233-92B, which did not specifically secrete TNF,
was tested, TIL plus antiTNF antibody were effective, but
significantly less so than TIL plus rabbit IgG control (Fig.
3,Exp. 3 : TIL + antiTNF vs . TIL + rabbit IgG, p = 0.037.)
Thus, it appears that for some but not all TIL, secretion of
TNF may play a role in tumor eradication .
The in vitro cytolytic specificity of murine TIL (Fig. 1
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and Table 1) indicates that antigens are detected by TIL on
someMCAinduced tumors and not on others. The observa-
tion that the therapeutic effectiveness of these TIL in vivo
is similarly specific (Fig. 1 and Table 1) suggests that the an-
tigenic determinant identified in vitro is also detected in vivo
and is a determinant of importance in the eradication of tumor
by TIL. However, the correlation between in vitro cytotox-
icity and in vivo effectiveness does not prove that the mecha-
nism oftumor regression in vivo is direct cytolysis by adop-
tively transferred cells. In fact, the demonstration that a
noncytolytic CD8+ TIL culture was effective in vivo (Tables
2 and 3) indicates that cytotoxicity is not a necessary require-
ment for CD8+ lymphocytes to mediate tumor regressions.
The observation that these nonlytic TIL were effective even
when a host CTL response was ablated with 500-rad irradia-
tion indicates that these TIL are not activating host CTL,
but instead may be mediating tumor regression through their
effects on radiation-resistant host effector cells such as mac-
rophages .
These results led us to investigate whether TIL secreted
lymphokines, which might activate host effector cells. There
is evidence that certain lymphokines are secreted by cytolytic
T cells . Murine CD8+ lymphocyte clones have been shown
to secrete IFN - 'y in response to stimulation with allogeneic
cells (27), Con A (28), and anti-CD3 mAb (29) . Anti-CD3
mAb-stimulated clones were also found to secrete TNF, GM-
CSF, and IL3 (29) . Furthermore, one group has reported that
a cytolytic CD8+ lymphocyte clone specifically reactive with
a murine malignant glioma will secreteIFN-'y in vitrowhen
stimulated with tumor cells (13) .
The data in Tables 8 and 10 show that IFN-y was specifically
secreted in 14 of 15 tests on TIL cultures that were simul-
taneously shown to be therapeutically effective, and in 23 of
23 tests on effective TIL "cloids" . When bulk TIL were ana-
lyzed, in 10 of 11 tests, ineffective TIL did not specifically
secrete IFN-y . In contrast, only 8 of 15 effective TIL cultures
were specifically cytolytic (Table 7) . These data indicate that
secretion ofIFN-y may be a better predictor of the in vivo
antitumor efficacy of aTIL culture than cytotoxicity . We are
currently evaluating whether a similar relationship exists be-
tween the pattern of lymphokine secretion and therapeutic
efficacy of human TIL cultures.
The high correlation observed between IFN-y secretion
in vitro and therapeutic efficacy suggests that the secretion
of IFN-y is a necessary part ofthe mechanism of tumor eradi-
cation by CD8+ lymphocytes. The five experiments (Fig. 2)
demonstrating that anti-IFN-y mAb inhibits the effective-
ness of four different TIL cultures from three different tumors
strongly support the hypothesis that secretion ofIFN-y is
an essential part of the mechanism whereby cytolytic CD8+
lymphocytes mediate tumor regression .
The role ofTNF in the mechanism of tumor eradication
by CD8+ lymphocytes has also been addressed by these ex-
periments. The observation that many TIL that did not
specifically secrete TNF were effective in vivo (Tables 4 and
7) indicates that specific secretion of TNF is not necessary
for the in vivo antitumor effectiveness of CD8+ lympho-
cytes. However, the constitutive release of low levels ofTNFby these TIL may, in concert with other lymphokines, have
a role in tumor regression. Since TIL that specifically secreted
TNF were therapeutically effective in six of six tests on TIL
cultures and in 21 of 22 testson TIL cloids, the specific secre-
tion of TNF may be a sufficient condition for in vivo effec-
tiveness. Of note, all of these effective TIL also specifically
secreted IFN-y.
The effect of antiTNF antibody on TIL effectiveness in
vivo (Fig. 3) demonstrates that for one TIL clone (205-87),
TNF secreted either by TIL, or by host effector cells acti-
vated by TIL, plays an integral role in tumor eradication.
It is possible that the anti TNF antibody abrogated TIL effec-
tiveness by binding to and eliminating TNF-secreting TIL.
However, we feel that this is highly unlikely since we have
not been able to demonstrate binding of the antiTNF anti-
body used in the experiments reported here to activated mac-
rophages or stimulated TIL (our unpublished observations) .
The lack of effect of anti TNF antibody on TIL culture 105-
53, although this culture specifically secretes TNF, indicates
that for this culture TNF secretion does not appear to be
a part of the mechanism of tumor regression.
The specific local secretion of IFN-y or TNF by TIL at
the site of a tumor may lead to tumor regression in several
ways. There is in vitro evidence that IFN-y and TNF are
directly cytotoxic to some tumors (30, 31). However, nei-
ther lymphokine is cytotoxic at high concentrations in vitro
to the MCA sarcomas we have used (our unpublished obser-
vations). Furthermore, when supernatants from TIL that were
high lymphokine secretors were incubated with multiple MCA
targets in 18-h 5'Cr release assays, no cytotoxicity was ob-
served (our unpublished observations). Therefore, it is un-
likely that lymphokines secreted by TIL are directly cyto-
toxic in vivo. IFN-y has also been implicated in the generation
of CTL from resting precursors (32, 33) . Although the mice
used in the antibodyblocking experiments described here were
not pre-irradiated, the ability of TIL to effectively eradicate
tumors in pre-irradiated animals (Tables 1 and 3) makes it
unlikely that IFN-y activation of host CTL plays an impor-
tant role in tumor eradication.
Specific local secretion of IFN-y or TNF may modulate
the tumor to increase its lysabilityby CTL. IFN-y has been
shown in vitro and in vivo to upregulate MHC class I an-
tigens on the sarcomas used in our experiments (34, 35). This
increase in MHC class I expression may explain the observa-
tion that MC 38 tumor cells treated with IFN-y and TNF
in vitro were lysed by a TIL that failed to lyse untreated tumor
cells, whereas nonspecific LAK lysis of the target was un-
affected (35). Furthermore, administration of IFN-y and TNF
with these TIL plus rIIr2 enhanced the in vivo effectiveness
of the TEL (35). Therefore, through modification ofthe tumor,
secreted IFN-y and TNF may enhance a cytolytic mecha-
nism of tumor eradication by TIL.
The local secretion of IFN-y by a CD8+ lymphocyte at
a tumor site may also lead to tumor regression by initiating
a DTH reaction. Cloned murine CD8+ lymphocytes have
been shown to be capable of mediating DTH reactions (36).
The importance ofIFN-y in the initiation of DTH has been
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established through the use of anti-IFN-y antibodies to block
DTH in mice (37) and to prevent lymphocyte recruitment
at the site of LPS-induced DTH in the rat (38). Adherence
of lymphocytes to endothelial cells in the post-capillary venule,
the first step in the migration oflymphocytes out of the blood
to sites of inflammation, is markedly stimulated by IFN-y
in vitro (39). Thus, secretion by TIL of IFN-y at the site
of a tumor may serve as a homing signal for lymphocyte
recruitment. Furthermore, local secretion ofIFN-'r (and TNF)
at a tumor site may induce the priming (and triggering) steps
necessary for the activation ofcytotoxic macrophages (40-42).
The levels of IFN-y present in supernatants ofTIL that have
been stimulated by tumor in vitro (i.e., 20 U/ml) are sufficient
to activate tumoricidal macrophages (26, 41). Also consis-
tent with a role for macrophages as the effectors of CD8+
lymphocyte-mediated tumor regressions are the results of ex-
periments in which tumor-bearing mice are pre-treated with
carageenan or Trypan blue, which are toxic to macrophages
but not lymphocytes. Adoptive immunotherapy with immune
splenocytes was ineffective when mice were pre-treated with
these agents (43).
A role for macrophages in a DTH reaction as at least a
part of the mechanism by which CD8+ lymphocytes me-
diate tumor regressions has important biological implications.
It has been proposed that immunotherapy failures, resulting
from the treatment of tumors composed of cells that may
have considerable antigenic heterogeneity with antigen-specific
agents (e.g., TIL), may be due to the selection of resistant
cells with quantitative or qualitative differences in antigen
expression (44). The nonselective destructive capabilities of
macrophages have made it extremely difficult to select, in
vitro, tumor cells resistant to macrophage-mediated lysis (45).
Therefore, if macrophages are the effector arm of a process
initiated by a specific TIL, it would be unlikely that differ-
ences in antigen expression would account for immunotherapy
failures.
Knowledge ofthe characteristics ofadoptively transferred
cells that are important determinants oftheirability to eradicate
tumor cells in vivo may help in the development of more
effective adoptive immunotherapy strategies. We are currently
investigating different methods of TIL culture to optimize
the growth conditions for TIL that are high lymphokine
secretors. Furthermore, the transduction ofgenes coding for
lymphokines involved in the process of tumor eradication into
TIL may allow higher concentrations of lymphokines to be
released at the tumor site, which may enhance the immune-
mediated process of tumor destruction. We have adoptively
transferred TIL to melanoma patients that were transduced
with a gene conferring Neomycin resistanceand demonstrated
that transduced TIL localize to tumor deposits and persist
in the host (46). Recently, Miyatake and co-workers (47, 48)
transduced IFN-y cDNA into a cloned CTL specific for a
murine glioma, and observed that the transduced clone was
more effective than the parent in Winn assays and in the im-
munotherapy of subcutaneous tumors. We are actively inves-
tigating the properties of human TIL transduced with the
cDNA for TNF and other lymphokines.
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